SS Innovations International (NASDAQ: SSII) reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year, signaling continued momentum for its SSi Mantra surgical robotic platform. The company also posted a 20.0% rise in gross profit to $7.1 million, though gross margin dipped to 50.9% from 59.1% in the prior-year quarter (https://nnw.fm/zxrT1).
For the first half of 2026, revenue surged 65.6% to $25.0 million from $15.1 million in the first half of 2025. Gross profit climbed 77.5% to $12.4 million, with an improved gross margin compared to the first half of last year. The company attributed the growth to increased installations of the SSi Mantra system, which rose 30.4% to 30 systems during the quarter, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, underscoring its clinical adoption.
Beyond the financial results, regulatory advancements are emerging as potential catalysts for SS Innovations. The company is targeting U.S. Food and Drug Administration (FDA) clearance for the SSi Mantra by the first quarter of 2027 and European CE marking by the end of 2026. Achieving these milestones would open access to two of the world’s largest medical device markets, potentially accelerating revenue growth and broadening the system’s global footprint.
The company’s telesurgery initiatives are also enhancing the clinical profile of the SSi Mantra. By demonstrating the ability to perform remote surgeries, SS Innovations is positioning the platform as a versatile tool that can extend surgical expertise to underserved areas. While telesurgery adds to the system’s appeal, installations remain the primary commercial driver, with each new installation representing a recurring revenue opportunity through service and instrument sales.
Investors and industry analysts are closely watching SS Innovations as it navigates the regulatory landscape and scales its operations. The strong revenue growth and expanding installed base suggest that the SSi Mantra is gaining traction in a competitive market dominated by established players. However, the company faces risks including regulatory hurdles, competition, and the need to manage costs effectively, as evidenced by the slight margin contraction in the latest quarter.
As SS Innovations continues to execute on its strategy, the successful attainment of FDA and CE approvals could prove transformative, not only for the company but also for healthcare providers seeking affordable and innovative robotic surgery options. With a growing base of systems and a pipeline of regulatory milestones, SS Innovations is poised to make significant strides in the global surgical robotics arena.
